Streetbeat News

Products Services

LLY

NVO

Doctors are facing challenges in securing Medicare coverage for Novo Nordisk's weight-loss drug Wegovy, despite its potential benefits for heart patients. Medicare's legal restrictions on covering weight-loss drugs and the high cost of Wegovy are significant barriers. Novo Nordisk is working with policymakers to improve coverage, and there is hope for better coverage next year. Eli Lilly's obesity drug Zepbound may also impact the market if it gains FDA approval for treating obstructive sleep apnea.

Portfolio Pulse from Vandana Singh

August 16, 2024 | 5:59 pm

ORGN

Origin Materials, Inc. (NASDAQ:ORGN) shares surged after reporting Q2 financial results. Despite missing earnings and sales estimates, the company secured a 2-year MOU for PET closure production, projected to generate over $100 million in revenue starting in 2025. BofA Securities upgraded ORGN to Buy, raising the price target to $3.00, citing potential profitability as early as 2026 and significant long-term growth potential in its biomass conversion technology.

Portfolio Pulse from Lekha Gupta

August 16, 2024 | 5:58 pm

LLY

NVO

RHHBY

Roche missed out on acquiring a potential blockbuster weight-loss drug, orforglipron, which Eli Lilly acquired for $50 million and is projected to generate up to $14 billion annually by 2032. Roche's cautious approach, influenced by past setbacks, led to this missed opportunity. Roche re-entered the obesity market in 2023 but is expected to lag behind competitors like Eli Lilly and Novo Nordisk.

Portfolio Pulse from Vandana Singh

August 16, 2024 | 5:56 pm

GOVX

GeoVax Labs, Inc. (NASDAQ:GOVX) shares surged by 65.4% following the WHO's declaration of mpox as a global health emergency and the ECDC's new risk assessment. The ECDC recommends heightened preparedness and rapid response measures in the EU/EEA due to the risk of imported mpox cases from Africa.

Portfolio Pulse from Vaishali Prayag

August 16, 2024 | 5:40 pm

AMAT

AMCR

COHR

DIA

FLO

GDX

GLOB

HRB

IWM

MRVI

QQQ

RGEN

SPY

XLC

XLF

XLRE

XLY

Wall Street saw modest gains on Friday, driven by improved consumer sentiment and strong economic data. Gold hit a record high, boosting mining stocks, while oil prices dipped due to geopolitical developments. Key ETFs and stocks showed varied performances, with notable movements in H&R Block, Amcor, Applied Materials, Coherent, Flower Foods, Globant, and Repligen.

Portfolio Pulse from Piero Cingari

August 16, 2024 | 5:38 pm

AAPL

AMD

DELL

INTC

MCHP

MSFT

NVDA

PLTR

SKYT

TSM

The article highlights significant options activity in the Information Technology sector, focusing on trades involving companies like AAPL, MSFT, NVDA, AMD, INTC, TSM, DELL, SKYT, PLTR, and MCHP. These activities could indicate potential trading opportunities based on the sentiment and volume of the trades.

Portfolio Pulse from Benzinga Insights

August 16, 2024 | 5:35 pm

TNXP

Tonix Pharmaceuticals' live virus vaccine candidate, TNX-801, shows long-term protection from mpox and smallpox with a single dose in animal studies. The company is advancing its development, and the vaccine has been selected by the NIH for Project NextGen. The stock saw a 4.01% increase, trading at $0.48.

Portfolio Pulse from Vandana Singh

August 16, 2024 | 5:29 pm

AAPL

Financial giants have shown a bullish trend in Apple (NASDAQ:AAPL) options trading, with 47 unusual trades identified. 46% of traders were bullish, while 42% were bearish. Significant trades include both puts and calls, with a focus on a price band between $70.0 and $240.0. The average open interest for Apple options is 12,278.3, with a total volume of 695,827.00. Expert opinions on Apple remain positive, with target prices ranging from $186 to $285.

Portfolio Pulse from Benzinga Insights

August 16, 2024 | 5:16 pm

DRUG

Bright Minds Biosciences Inc. (NASDAQ:DRUG) reported a significant reduction in net losses for Q3 2024, driven by the timing of program starts and completions within their drug portfolio. The company holds $6.2 million in cash and raised $900,000 through equity financing. Ongoing R&D efforts focus on 5-HT2C and 5-HT2A receptor agonists, with successful Phase 1 trials and preparatory work for Phase 2 studies. Despite progress, the company faces risks related to regulatory approvals, financing, and clinical trial uncertainties.

Portfolio Pulse from Juan Spínelli

August 16, 2024 | 5:11 pm

VRNOF

Mike Tyson's cannabis brand, TYSON 2.0, is expanding into Florida and Illinois through a partnership with Verano Holdings Corp. (CSE:VRNO, OTCQX:VRNOF). The deal will leverage Verano's cultivation facilities and dispensaries to distribute TYSON 2.0 products, including Mike Bites edibles and vape cartridges. This expansion aims to enhance TYSON 2.0's market presence in these states.

Portfolio Pulse from Jelena Martinovic

August 16, 2024 | 5:06 pm